Vir Biotechnology

$27.23
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.68 (-2.45%) As of 3:18 PM UTC today

Why Robinhood?

You can buy or sell VIR and other stocks, options, and ETFs commission-free!

About VIR

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA. The listed name for VIR is Vir Biotechnology, Inc. Common Stock.

CEO
George A. Scangos
Employees
229
Headquarters
San Francisco, California
Founded
2016
Market Cap
3.46B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.23M
High Today
$27.94
Low Today
$26.76
Open Price
$27.94
Volume
158.08K
52 Week High
$75.00
52 Week Low
$11.65

Collections

VIR Earnings

-$4.60
-$3.07
-$1.53
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
-$0.60 per share
Actual
-$0.67 per share

You May Also Like